DRUG WATCH |
|
Year : 2015 | Volume
: 47
| Issue : 1 | Page : 121-122 |
Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment
Hasan Tahsin Gozdas, Oguz Karabay
Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of Medicine, Sakarya, Turkey
Correspondence Address:
Dr. Hasan Tahsin Gozdas Department of Infectious Diseases and Clinical Microbiology, Sakarya University Faculty of Medicine, Sakarya Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.150377
Peginterferon alpha-2a (PEG IFN α-2a) is frequently used in chronic hepatitis B (CHB)treatment. Numerous adverse events can be noted during this therapy such as flu-like disease, rash, weight loss and depression. However, PEG IFN α-2a related ototoxicity seems to be an uncommon entity. Ototoxicity can be detected objectively by audiometry. In this paper, we present a case of CHB who developed reversible bilateral ototoxicity during PEG IFN α-2a treatment. Due to ototoxicity detected objectively by audiogram, treatment was ceased at sixth month and ototoxicity completely recovered one month after stopping the drug.
[FULL TEXT] [PDF]*
|